Drug Trial Radar · NCT07194382
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Mar 10, 2026
Primary completion
Dec 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- Avalyn Pharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the impact Nintedanib Solution for Inhalation (AP02) has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF) as well as assess its safety and tolerability. Adults 40 years of age or older with IPF who meet the inclusion and exclusion criteria can participate in this study if they are not currently on treatment for IPF, and if treated with oral nintedanib or pirfenidone, have stopped the medication for at least 3 months. Researchers will compare two different doses of AP02 to a placebo (a look-alike substance that contains no drug) to see if AP02 works to treat IPF. Participants are put into 1 of 3 groups randomly, which means by chance and will take AP02 or a placebo two times every day for 12 weeks by using a nebulizer, which is a device that provides medicine to the lungs via inhalation. Participants will visit the office 6 times and receive 1 phone call over a 16-week period. At site visits doctors regularly perform breathing tests that measure how well the lungs are working, give the patient questionnaires and will check the participants' health.
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
AP02Drug
Oral inhalation solution
PlaceboDrug
Placebo oral inhalation solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the morning pre-dose forced vital capacity at Week 12Time frame: From enrollment to the end of treatment at 12 weeks
Locations
49 sites in 7 countries. Site status is shown where the registry gives one.
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia · Recruiting
Nepean Lung and Sleep
Kingswood, New South Wales, Australia · Recruiting
John Hunter Hospital
New Lambton Heights, New South Wales, Australia · Recruiting
Macquarie University Hospital
Sydney, New South Wales, Australia · Recruiting
Ludwig Engel Centre for Respiratory Research
Westmead, New South Wales, Australia · Recruiting
Launceston Respiratory and Sleep Centre
Launceston, Tasmania, Australia · Recruiting
Austin Health
Heidelberg, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
University of Calgary - Foothills Medical Centre
Calgary, Alberta, Canada · Recruiting
Centre for Lung Health - Vancouver General Hospital
Vancouver, British Columbia, Canada · Recruiting
Newfoundland and Labrador Health Services
St. John's, Newfoundland and Labrador, Canada · Recruiting
Queen Elizabeth
Halifax, Nova Scotia, Canada · Recruiting
Dynamic Drug Advancement
Ajax, Ontario, Canada · Recruiting
University Health Network - Toronto General Hospital
Toronto, Ontario, Canada · Recruiting
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada · Recruiting
Jewish General Hospital
Montreal, Quebec, Canada · Recruiting
Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hôpital Fleurimont
Sherbrooke, Quebec, Canada · Recruiting
CIC Mauricie
Trois-Rivières, Quebec, Canada · Recruiting
Universitätsklinikum Heidelberg - Thoraxklinik Heidelberg
Heidelberg, Germany · Recruiting
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany · Recruiting
Pneumologisches Studienzentrum München-West
Munich, Bavaria, Germany · Recruiting
Studienzentrum Dr. Keller
Frankfurt am Main, Hesse, Germany · Recruiting
Greenlane Clinical Centre
Auckland, New Zealand · Recruiting
Christchurch Hospital
Christchurch, Cantebury, New Zealand · Recruiting
Waikato Hospital
Hamilton, Waikato Region, New Zealand · Recruiting
Hospital Clínic de Barcelona
Barcelona, Spain · Recruiting
Hospital HM Sanchinarro
Madrid, Spain · Recruiting
Hospital Universitario de la Princesa
Madrid, Spain · Recruiting
Hospital Universitario Virgen de la Victoria
Málaga, Spain · Recruiting
Hospital Germans Trias i Pujol/Hospital Can Ruti
Badalona, Barcelona, Spain · Recruiting
Hospital General de Granollers, Barcelona
Granollers, Barcelona, Spain · Recruiting
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain · Recruiting
Hospital Universitario de Bellvitge
L'Hospitalet de Llobregat, Catalonia / Barcelona, Spain · Recruiting
Consorci Corporació Sanitària Parc Taulí (Parc Taulí Hospital Universitari)
Sabadell, Catalonia / Barcelona, Spain · Recruiting
Istanbul University Cerrahpasa Hospital
Istanbul, Turkey (Türkiye) · Recruiting
Gülhane Saglik Bilimleri Fakültesi
Keçiören, Turkey (Türkiye) · Recruiting
University Hospitals Birmingham NHS Foundation Trust - Heartlands Hospital
Birmingham, United Kingdom · Recruiting
Royal Papworth Hospital NHS Foundation Trust
Cambridge, United Kingdom · Recruiting
Aintree University Hospital
Liverpool, United Kingdom · Recruiting
Royal Brompton Hospital, Guy's and St Thomas NHS Foundation Trust
London, United Kingdom · Recruiting
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.